Le Lézard
Classified in: Health, Business
Subjects: STOCK/OTHER MARKET NEWS, HEALTH

EXMceuticals inc. applies for a for a voluntary management cease trade order


VANCOUVER, British Columbia, Oct. 23, 2019 (GLOBE NEWSWIRE) -- EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the "Company" or "EXM") announces that it has applied for a voluntary management cease trade order in accordance with National Policy 12-203 due to it not being able to file its annual financial statements and MD&A for the year ended June 30, 2019 on SEDAR within 120 days of its financial year-end.

The Company requires additional time to file its annual financial statements and MD&A for the financial year ended June 30, 2019 due to this being the first annual financial statements of the consolidated company following an RTO and additional time is required to complete the review and procedures.  As a result, the Company concluded that it would not be in a position to complete the year-end audit within the time periods required by National Instrument 51-102.  The Company currently anticipates that it will be in a position to file its annual financial statements and MD&A for the year ended June 30, 2019 on or before December 28, 2019.

The Company intends to satisfy the provisions of the alternative information guidelines of National Policy 12-203 until the revocation of the management cease trade order.  The Company is not subject to any insolvency proceedings.

ON BEHALF OF THE BOARD OF DIRECTORS OF EXMCEUTICALS INC.

Michel Passebon, Chief Executive Officer and Director

For further information contact:
Investor Relations
Email: [email protected]

Media Enquiries:
Email: [email protected]
Europe - Jane Glover:  +44 (0) 203 757 4990
North America - Mélanie Guillemette: +1 819 668 2734

FOR MORE UPDATES ON THE COMPANY

Follow us on Twitter: https://twitter.com/EXMceuticals
Follow us on LinkedIn: https://www.linkedin.com/company/exmceuticals/

Neither the CSE nor the FSE has approved nor disapproved the contents of this news release.  Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.


These press releases may also interest you

at 16:10
Arcus Biosciences , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on...

at 16:05
biote Corp. ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide first quarter financial...

at 16:02
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a new initiative aimed to help reimagine the home environment as an integral part of the health care system....

at 15:52
Getlabs, the nationwide leader for at-home diagnostics, is excited to announce a strategic partnership with Instalab, a pioneering proactive healthcare company. Through Getlabs' widespread presence throughout the United States, Instalab can provide...

at 15:45
Core Sound Imaging, creator of the Studycast system, today announces that Core Sound Imaging was named a 2024 SIIA CODiE Award Finalist in the Most Innovative Tech Company category. CODiE Finalists represent the best products, services and people in...

at 15:43
Today marks the release of the 2024 National Strategy for Suicide Prevention, an important milestone and rallying point for organizations nationwide working to address this important public health issue. The American Foundation for Suicide Prevention...



News published on and distributed by: